An application method of at least one of a THBS1 protein and a THBS3 protein as biomarkers for detecting acute myocardial infarction is provided, which belongs to the field of biomedical technology. The THBS1 protein and THBS3 protein in peripheral plasma are low expressed in patients with acute myocardial infarction through proteomic results, the proteomic results are verified by expanding the number of patients’ samples, and the two proteins can be used as molecular markers for the diagnosis of acute myocardial infarction. It has the advantages that: (1) peripheral blood samples are easy to obtain, saving time and labor; (2) the experiment is simple and easy to operate; (3) a new intervention target for diagnosis and treatment of acute myocardial infarction is found; (4) a new direction is provided for treating acute myocardial infarction and improving prognosis in the future; and (5) a new idea is provided for precision medicine.

Abstract The disclosure provides a reagent comprising a leuco dye and a compound represented by Formula (I): ##STR00001## where R represents a hydrocarbon chain having 8 to 17 carbon atoms, the reagent for measuring glycoprotein, a kit comprising the reagent and a second reagent, and methods of measuring hemoglobin A1c using the reagent.

The present invention relates to a method for the diagnosis, prognosis, risk assessment, risk stratification, monitoring, therapy guidance and/or therapy control of a fungal infection, in particular invasive fungal infections (IFI) and/or the ruling in or ruling out of an fungal infection and/or the differential diagnosis of a fungal colonization vs. an invasive fungal infection in a subject, wherein in particular the subject has an increased risk of getting or having a fungal infection and/or the subject is in a critical disease state, particularly has an existing infection and/or a state of sepsis, particularly a septic shock. The method of the invention comprises determining the level of at least one marker selected from the group of ICAM1, AHSG, CPN1, FABP1, HRG, PIGR, RAP1A, THBS1, VCL, ET-1. Furthermore, the invention relates to a diagnostic assay and a kit for carrying out the method.

Disclosed herein are methods and compositions related to antibody fragments which specifically bind sialyl-Tn epitope of tumor-associated glycoprotein 72 (TAG-72).

Fucosylated α.sub.1-acid glycoprotein (fAGP) was found to be useful for the diagnosis of pancreatic cancer and malignant intraductal papillary mucinous neoplasm (IPMC), resulting in the finding of a new biomarker for pancreatic cancer or malignant intraductal papillary mucinous neoplasm (IPMC), in particular, a new biomarker useful for rapid diagnosis of malignant intraductal papillary mucinous neoplasm (IPMC) that increases the accuracy of malignant intraductal papillary mucinous neoplasm (IPMC) and aids conventional imaging diagnosis by making a suitable preoperative diagnosis of a benign neoplasm or a malignant neoplasm in intraductal papillary mucinous neoplasm (IPMN).

The invention is directed to engineered Fc gamma receptor type III (FcγII, HNA-1) polypeptides and use of these polypeptides to detect antibodies specific for human neutrophil antigens (HNA). The invention is also directed to methods for the diagnosing and determining susceptibility for developing Transfusion Reaction Acute Lung (TRALI).

Provided are methods and compositions for the diagnosis and treatment of COVID-19, a disease caused by SARS-CoV-2 infection. More specifically, peptides that bind to SARS-CoV-2 are provided for use as diagnostic and therapeutic compositions in diagnosis, treatment and prevention of individuals contracting, or in danger of contracting COVID-19.

The present invention relates to the field of cancer. Specifically, the present invention provides compositions and methods useful for detecting and treating aggressive prostate cancer. In another embodiment, a method for identifying a subject as having aggressive prostate cancer comprises the step of measuring one or more of ACPP, CD63, KLK 11, ATRN, GP2, PTPRN2, NPTN, RNASE2, CPE, SERPINA1, DSC2, PTGDS, GRN, LRG1, UMOD, CLU, LOX, ORM1, CD97, PSA and AFM in a urine sample obtained from the subject, wherein a decreased level of one or more of ACPP, CD63, KLK 11, ATRN, GP2, PTPRN2, NPTN, RNASE2, PSA, CPE and/or an increased level of one or more of SERPINA1, DSC2, PTGDS, GRN, LRG1, UMOD, CLU, LOX, ORM1, CD97, and AFM relative to a control identifies the subject as having aggressive prostate cancer. In another embodiment, the method further comprises the step of treating the subject with a prostate cancer therapy.

Provided herein are methods for determining the efficacy of treatment for polycystic kidney disease (PKD) in a patient, diagnosing PKD in a patient, staging PKD in a patient, and monitoring PKD in a patient. These methods include determining a single or multiple levels of AMBP. Also provided are kits that include an antibody specifically binds to AMBP protein and at least one antibody that specifically binds to an additional marker of PKD.

The present invention provides compositions and methods for identifying subjects suffering from dry eye that can be treated by topical administration of a composition comprising lacritin or a bioactive fragment thereof. The application discloses in part that a ˜90 KDa deglycanated form of syndecan-1 is abundant in tears of normal individuals but not individuals suffering from dry eye, whereas a ˜25 kDa syndecan-1 fragment is detectable in dry, but not normal tears.